End-of-day quote
Shenzhen S.E.
06:00:00 2024-06-13 pm EDT
5-day change
1st Jan Change
4.19
CNY
-0.95%
+2.44%
-30.97%
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019
August 28, 2019 at 03:15 pm EDT
Shandong Wohua Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was CNY 417.880 million compared to CNY 357.989 million a year ago. Operating income was CNY 33.924 million compared to CNY 51.070 million a year ago. Net income was CNY 31.271 million compared to CNY 37.948 million a year ago. Basic earnings per share from continuing operations was CNY 0.09 compared to CNY 0.11 a year ago.
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 26
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 29
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-26
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-07-28
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-26
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-27
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-07-15
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-15
CI
Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments
22-02-11
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-01-20
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-28
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
21-07-29
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-06
CI
Beijing Tongfengtang Pharmaceutical Management Co., Ltd. cancelled the acquisition of Wohua Pharmaceutical International Co., Ltd. from Shandong Wohua Pharmaceutical Co., Ltd..
21-03-26
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
21-01-20
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
20-10-15
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
20-07-15
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
20-04-28
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020
20-04-28
CI
Beijing Tongfengtang Pharmaceutical Management Co., Ltd. entered into a share transfer agreement to acquire Wohua Pharmaceutical International Co., Ltd. from Shandong Wohua Pharmaceutical Co., Ltd. for CNY 90 million.
20-03-27
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
19-10-28
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019
19-08-28
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2019
19-04-28
CI
Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018
19-01-31
CI
Shandong Wohua Pharmaceutical Co., Ltd. Announces Earnings Results for the Third Quarter and Nine Months Ended September 2015
15-10-09
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Shandong Wohua Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of Chinese traditional patent medicines. The Company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Gushu tablets for the treatment of middle-aged and senile osteoporosis, and Hedan tablets for promoting blood circulation and for the treatment of hyperlipidemia. The Company distributes its products in domestic market, mainly in East China, North China and Northeast China.
More about the company
1st Jan change
Capi.
-30.97% 333M +32.48% 5.8B -26.22% 3.92B +4.73% 3.28B -20.86% 2.77B -11.88% 2.26B +46.64% 1.95B -16.71% 1.52B +44.65% 1.49B -9.60% 1.49B
Alternative Medicine
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1